IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock Holdings Lowered by Farther Finance Advisors LLC

Farther Finance Advisors LLC lowered its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 20.9% in the 4th quarter, Holdings Channel reports. The fund owned 637 shares of the company’s stock after selling 168 shares during the period. Farther Finance Advisors LLC’s holdings in IDEXX Laboratories were worth $263,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. FSA Wealth Management LLC bought a new position in shares of IDEXX Laboratories during the third quarter worth about $25,000. Rialto Wealth Management LLC bought a new position in shares of IDEXX Laboratories during the fourth quarter worth about $30,000. Retirement Wealth Solutions LLC bought a new position in shares of IDEXX Laboratories during the fourth quarter worth about $31,000. Kestra Investment Management LLC bought a new position in shares of IDEXX Laboratories during the fourth quarter worth about $38,000. Finally, Crews Bank & Trust bought a new position in shares of IDEXX Laboratories during the fourth quarter worth about $41,000. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX opened at $419.52 on Wednesday. IDEXX Laboratories, Inc. has a twelve month low of $398.50 and a twelve month high of $548.88. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The company has a 50-day moving average of $437.74 and a 200-day moving average of $445.87. The firm has a market cap of $34.12 billion, a price-to-earnings ratio of 39.32, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on IDXX shares. Barclays increased their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research report on Tuesday, February 4th. Piper Sandler increased their target price on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. Morgan Stanley decreased their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research report on Wednesday, January 29th. Leerink Partners initiated coverage on shares of IDEXX Laboratories in a research report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 target price for the company. Finally, Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, IDEXX Laboratories has an average rating of “Moderate Buy” and an average price target of $533.75.

Insider Activity

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the company’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the sale, the director now directly owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP George Fennell sold 9,986 shares of the company’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares of the company’s stock, valued at $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.11% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.